 |
2 Diseases |  |
32 Trials |
|
32 Trials |  |
1662 News |  |
| «12...7891011121314151617...2425» |
- || Prevymis (letermovir) / Merck (MSD)
The results with letermovir are such that you would need a huge study to prove superior outcomes. Unlikely to be done. COI I have advised MSD and received research support. (Twitter) - Apr 26, 2022
- || Prevymis (letermovir) / Merck (MSD), Vistide (cidofovir) / Gilead
In fact we can consider cidofovir vs letermovir in prophylaxis/ early preemptive strategy ( as funded study) (Twitter) - Apr 26, 2022
- |||| Prevymis (letermovir) / Merck (MSD)
Clinical: Anyone in favor of a study comparing Letermovir vs Leflunamide as CMV Prophylaxis in Haplo/MUD ? Does anyone see any clinical rationale here , just a thought ! @BldCancerDoc @dgomezalmaguer @ReetuJain19 @RahulDoc2 @DrNeha90356702 @ASTCT @satya_yadav @RanjitKSMD (Twitter) - Apr 26, 2022
- ||| Prevymis (letermovir) / Merck (MSD)
Our work on letermovir ppx in HCT cited as one of the top 10 papers in oncology/HCT ID at #ECCMID2022. Letermovir ppx reduces incidence of R/R CMV and of NRM at 48 wks. Thanks @Carlotasway3 for mentioning us and @MichaelGIsonMD for reporting it! @ChemalyRoy #IDTwitter #TxID #CMV (Twitter) - Apr 25, 2022
- || Prevymis (letermovir) / Merck (MSD)
Letermovir and incidence of refractory or resistant CMV https://t.co/SCYisLeH35 (Twitter) - Apr 25, 2022
- || Prevymis (letermovir) / Merck (MSD)
Letermovir Prophylaxis and survival. https://t.co/meuG1NKUCv (Twitter) - Apr 25, 2022
- ||| Prevymis (letermovir) / Merck (MSD)
Another @fredhutch spotlight at #Tandem22, work by @zamora_danniel @HutchIDScience on impaired T cell reconstitution after Letermovir prophylaxis. (Twitter) - Apr 24, 2022
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients. (Pubmed Central) - Apr 22, 2022
No abstract available
- || Prevymis (letermovir) / Merck (MSD), Livtencity (maribavir) / Takeda, GSK
Thank you! VL nadir on maribavir was ~650 and is now > 12K. Mutations right before starting maribavir were UL97 L595S and UL54 Q578H, we’re repeating now. Definitely worried about adding in letermovir d/t current VL and losing secondary ppx (Twitter) - Apr 21, 2022
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical, Pricing: I picked the realistic cost I was charged for chemo. Letermovir is over 5K and that is just a prophylaxis. Yes the research that goes into these drugs/biologics are $$$$ but that cost shouldn't be passed on to the patients who are in a live or die situation. Most want to live. (Twitter) - Apr 20, 2022
- | Prevymis (letermovir) / Merck (MSD)
Journal: Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan. (Pubmed Central) - Apr 20, 2022
Letermovir is a promising medication for use in cytomegalovirus prophylaxis in children. Further studies are warranted.
- || Prevymis (letermovir) / Merck (MSD)
Btw, we put all our at risk (R+) getting PTCy allos including Haplos on letermovir starting day +7 and see very low rates of significant cmv viremia. (Twitter) - Apr 18, 2022
- || Prevymis (letermovir) / Merck (MSD), acyclovir / Generic mfg.
No letermovir in India. Acyclovir or Valacylovir for prophylaxis. (Twitter) - Apr 17, 2022
- || Prevymis (letermovir) / Merck (MSD), foscarnet / Generic mfg.
Favor foscarnet, with PTCy and early viremia, should be considering what prophy/monitoring (including other viruses) should occur after viremia is cleared. Would anyone use 2nd prophylaxis w/ letermovr if viremia occurred before letermovir? IVIG repletion? (Twitter) - Apr 17, 2022
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical: As I have voted I will immediately start foscornet. Waiting was an option with Sibling allograft as you generally do treat after 2 positivity. Important question is whether patient was on letermovir prophylaxis (Twitter) - Apr 17, 2022
- || Prevymis (letermovir) / Merck (MSD)
Observe + repeat Pcr and start letermovir . (Twitter) - Apr 17, 2022
- ||||| Prevymis (letermovir) / Merck (MSD)
Clinical: CMV alloBMT Risk factors: CMV+ recipient Pred >1 mg/kg T-cell depletion (ATG) aGVHD Monitor CMV PCR weekly Prophy = prevent viremia (infection) = letermovir Pre-emptive = Treat viremia to prevent dz (colitis, pneumonia, hepatitis) Treatment = see table https://t.co/iHj1ExyPN5 (Twitter) - Apr 17, 2022
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical: What's interesting is how would management change had the patient been on letermovir prophylaxis ! (Twitter) - Apr 16, 2022
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical: By 1200 it’s better to repeat the CMV PCR in 2 days to see if it’s really increasing, bevor starting the myelotoxic treatment. I assume, the patient is already on letermovir prophylaxis? (Twitter) - Apr 16, 2022
- || Prevymis (letermovir) / Merck (MSD)
If asymptomatic on letermovir continue until 1log increase. pp65 negative because no wbc 😉 (Twitter) - Apr 16, 2022
- | Prevymis (letermovir) / Merck (MSD)
Journal: Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program. (Pubmed Central) - Apr 14, 2022
At least one adverse drug reaction was reported for 12 patients (15.4%). In this early access program, letermovir was effective with comparable results of the phase 3 study with a low rate of clinically significant CMV infection, including in patients who were at high-risk for CMV infection.
- | Prevymis (letermovir) / Merck (MSD)
Journal: Reliable quantification of Cytomegalovirus DNAemia in Letermovir treated patients. (Pubmed Central) - Apr 13, 2022
However, qPCR shows to be a reliable method to evaluate antiviral efficacy of LMV in cell free specimens. These results have strong clinical implications for the monitoring of CMV therapy during LMV treatment.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. (Pubmed Central) - Apr 12, 2022
Moreover, letermovir prophylaxis significantly reduced both the incidence of CMV gastroenteritis (HR, 0.50; 95% CI, 0.25-0.99; P = 0.047) and the risk of nonrelapse mortality (HR, 0.72; 95% CI, 0.52-0.99; P = 0.043). In summary, CMV gastroenteritis is a life-threatening complication that sets the need for preventive strategies with letermovir and targeted surveillance.
- ||||||| Prevymis (letermovir) / Merck (MSD)
Trial completion: Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) (clinicaltrials.gov) - Apr 11, 2022
P3, N=601, Completed, Sponsor: Merck Sharp & Dohme Corp.
In summary, CMV gastroenteritis is a life-threatening complication that sets the need for preventive strategies with letermovir and targeted surveillance. Active, not recruiting --> Completed
- || Prevymis (letermovir) / Merck (MSD)
Letermovir for all CMV positive through day 100, longer if GVH. Sometimes as secondary prophy as well. PCR monitoring while on prophy as well (Twitter) - Apr 8, 2022
- || Prevymis (letermovir) / Merck (MSD)
#TxID Friends, how do your centers utilize letermovir? Ppx vs treatment? How long? Do you monitor cmv pcrs? @AST_IDCOP @CmvConference @KottonNelson @nikkitheomd @MichaelIsonMD @DocSaimaAslam @ASTCT @tmhohl71 @DrMiguelPerales @theIDPharmD @kcmolinaID @MatthewPCheng (Twitter) - Apr 8, 2022
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Retrospective data, Journal: Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis. (Pubmed Central) - Apr 6, 2022
Letermovir was well tolerated and effective during extended prophylactic courses with only one case of breakthrough CMV infection in this cohort of thoracic transplant recipients. Further prospective trials of letermovir prophylaxis in this population are warranted.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplant recipients following letermovir prophylaxis. (Pubmed Central) - Apr 6, 2022
LTV prophylaxis delays HCMV infection and HCMV-specific immune reconstitution, therefore immunological and virological monitoring should be implemented post-prophylaxis discontinuation. The potential effect of LTV prophylaxis in reducing chronic GvHD should be evaluated by prospective studies.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, PK/PD data, Journal: Pharmacokinetics and Safety of Letermovir and Midazolam Coadministration in Healthy Subjects. (Pubmed Central) - Apr 5, 2022
All treatments were generally well tolerated. Letermovir demonstrated moderate CYP3A inhibition.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, PK/PD data, Journal: The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers. (Pubmed Central) - Apr 5, 2022
No specific safety or tolerability concerns were identified. Overall, letermovir had no clinically relevant effect on concomitant administration with digoxin.
- | Prevymis (letermovir) / Merck (MSD)
Journal: Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants. (Pubmed Central) - Apr 5, 2022
Due to the increase in ATV exposure with letermovir coadministration, statin-associated adverse events such as myopathy should be closely monitored following coadministration. The dose of ATV should not exceed 20 mg daily when coadministered with letermovir.
- ||| Prevymis (letermovir) / Merck (MSD)
But if you have a haplo ptcy transplant with a NEG CMV recipient who has a Positive cmv donor , would you still use letermovir prophylaxis ? Thanks (Twitter) - Apr 1, 2022
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical: Exactly. All pos R+ pts get letermovir. (Twitter) - Apr 1, 2022
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical, P3 data: Phase 3 data in @NEJM showed clear benefit of letermovir ppx in all patients incl both high and standard risk for CMV. We use it in all R+ patients. (Twitter) - Apr 1, 2022
- |||| Prevymis (letermovir) / Merck (MSD)
Clinical: Because @CarmemBonfim1 piqued my curiosity with a Qs + letermovir is more widely used by adult docs, @ouholter @BldCancerDoc do you do letermovir ppx in all CMV D+/R- or only select pts (predefined criteria: ? serotherapy, heavily pretreated, past CMV etc).? whats the evidence? (Twitter) - Apr 1, 2022
- ||| Prevymis (letermovir) / Merck (MSD)
Clinical: Same here. All R+ patients get letermovir (FDA label is for recipient positive patients only). (Twitter) - Apr 1, 2022
- ||| Prevymis (letermovir) / Merck (MSD)
Trial completion, Enrollment change, Trial completion date: Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection (clinicaltrials.gov) - Mar 29, 2022
P2, N=10, Completed, Sponsor: Amy C. Sherman, MD
The dose of ATV should not exceed 20 mg daily when coadministered with letermovir. Recruiting --> Completed | N=32 --> 10 | Trial completion date: Dec 2022 --> Mar 2022
- Prevymis (letermovir) / Merck (MSD)
First description of letermovir resistance mutation in UL51 gene from a HSCT-patient and study of its impact on the terminase complex structure () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_1889;
- ||||||| Prevymis (letermovir) / Merck (MSD)
Trial completion, Post-transplantation: Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) (clinicaltrials.gov) - Mar 24, 2022
P3, N=220, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | N=32 --> 10 | Trial completion date: Dec 2022 --> Mar 2022 Active, not recruiting --> Completed
- Prevymis (letermovir) / Merck (MSD), Livtencity (maribavir) / Takeda, GSK
Updates and Controversies in Cytomegalovirus (Hynes Ballroom A) - Mar 23, 2022 - Abstract #ATC2022ATC_293;
Despite advances in immunosuppressive regimens, ultrasensitive viral diagnostics, and novel antiviral agents, CMV remains a significant cause of post-transplant morbidity and mortality. In this session, three experts will discuss cutting edge issues in the management of CMV in SOT recipients, including: the role of novel antivirals (maribavir and letermovir), implementation of immune monitoring and individualized prophylaxis strategies, and salvage therapies (cytotoxic T lymphocytes, etc.).
- || Prevymis (letermovir) / Merck (MSD)
#Letermovir prophylaxis #EBMT22 industry symposium: impact on 1-y NRM, possible preservation of CMV-CMI, need to define cutoff for PET start & particular need in the #PTCY era - by G Papanicolau, D Neofytos & M Stelljes (Twitter) - Mar 20, 2022
- |||| Prevymis (letermovir) / Merck (MSD), Livtencity (maribavir) / Takeda, GSK
Impressive presentation @ChemalyRoy from @MDAndersonNews about #Letermovir and #Maribavir as new strategies for #HSCT #CMV prophylaxis and treatment #EBMT22 @TheEBMT @TheEBMT_Trainee (Twitter) - Mar 20, 2022
- | Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
Journal: The Synthesis and Anti-Cytomegalovirus Activity of Piperidine-4-Carboxamides. (Pubmed Central) - Mar 17, 2022
Finally, the activity of analog 8 was additive with newly identified CMV inhibitors (MLS8969, NFU1827, MSL8554, and MSL8091) and with ganciclovir. Further structural activity development should provide promising anti-CMV agents for use in clinical studies.
- | Prevymis (letermovir) / Merck (MSD)
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - STEP 1 (CYMEVAL3-STEP1) (clinicaltrials.gov) - Mar 15, 2022
P=N/A, N=7, Completed, Sponsor: Assistance Publique - H
Further structural activity development should provide promising anti-CMV agents for use in clinical studies. Recruiting --> Completed | N=10 --> 7 | Trial completion date: Feb 2028 --> Nov 2021 | Trial primary completion date: Feb 2027 --> Nov 2021
- Prevymis (letermovir) / Merck (MSD)
Effectiveness of Letermovir for Cytomegalovirus Prophylaxis in Seropositive Allogeneic Hematopoietic STEM Cell Transplant Recipients: A Global Systematic Review (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1236;
However, ranges in all outcomes for LET demonstrated consistent improvement than ranges resulting in PET use, suggesting a trend in LET effectiveness over PET. Guidelines must focus on more standardized recommendations to facilitate the effectiveness of future studies.
- || Prevymis (letermovir) / Merck (MSD)
Clinical, Journal: Ways to boost cellular immunity in solid organ transplant recipients - the case of letermovir. (Pubmed Central) - Mar 3, 2022
Guidelines must focus on more standardized recommendations to facilitate the effectiveness of future studies. No abstract available
- | Prevymis (letermovir) / Merck (MSD)
Journal: Absorption, Metabolism, Distribution, and Excretion of Letermovir. (Pubmed Central) - Mar 1, 2022
No abstract available The body of work presented in this manuscript informed on the potential for DDIs when letermovir is administered both intravenously and orally in HSCT recipients.
- || Prevymis (letermovir) / Merck (MSD)
PK/PD data, Journal: Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics. (Pubmed Central) - Mar 1, 2022
OATP1B endogenous biomarkers coproporphyrin (CP) I and glycochenodeoxycholic acid-sulfate (GCDCA-S) were also analyzed; their exposures increased after single-dose rifampin plus letermovir, consistent with OATP1B inhibition and prior reports of inhibition by rifampin alone. CP I and GCDCA-S exposures were substantially reduced with letermovir administered 24 hours after the last dose of rifampin versus letermovir plus chronic rifampin coadministration, This study suggests that OATP1B induction may contribute to reduced letermovir exposure after chronic rifampin administration, although given the complexity of letermovir disposition, alternative mechanisms are not fully excluded.
- | Prevymis (letermovir) / Merck (MSD)
Journal: Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients. (Pubmed Central) - Feb 22, 2022
P3
There was no dependence between adverse event incidence and letermovir exposure. These results support current dosing recommendations in several countries and regions, including the US and EU.
- | Prevymis (letermovir) / Merck (MSD)
Journal: Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal. (Pubmed Central) - Feb 19, 2022
Among patients whose tacrolimus C/D ratio decreased ≥ 30%, three (9%) patients in the fluconazole group and one (4%) in the voriconazole group experienced worsening of GVHD. Careful monitoring of tacrolimus concentration is important after letermovir discontinuation to avoid worsening of GVHD due to decreased tacrolimus concentration.